I am currently attending an Infectious Disease conference at Harvard. I have seen several posters of dubious credibility whining about how management completely mismanaged the antimicrobial side of B. With that in mind, here is some food for thought concerning the role of newer antibiotics: A physician member of the Infection Control Unit at Massachusetts General Hospital and professor at Harvard Medical School related the current practice philosophy that newer antibiotics are valuable WHEN WE NEED THEM but are not routinely used as front line therapies as most infections are controllable with current therapies and many economic challenges exist for newer antimicrobial development. For those who bemoan the lack of drive in ABSSSI, consider the cases of other companies who have developed different versions of established antibiotic classes and their stock had a sudden ethereal rise and then plummeted. With a totally new class being introduced (B), the hill is much steeper. If you are into this stock for a quick buck, then tough s#$%. For those who are in it for the long haul, the current direction is a much smarter pragmatic approach.
Now, I am not saying that B's value as an antibiotic is nill, quite the contrary. I believe that it will eventually be extremely valuable and serves as a valuable asset for any BP who are researching its value. However, the current approach is much more efficacious and viable from a corporate standpoint. I am extremely comfortable with their approach. For what its worth, one of the HDMs which were mentioned from the Polymedix stable was an antifungal. Now THAT would be valuable in a much shorter time frame in my opinion.
For newer and older investors alike, please see through the BS of some posters. They have little knowledge which is usable.
